New MAPRx Report Examines the Exclusion of Anti-Obesity Medications in Medicare Part D
A new report commissioned by the MAPRx Coalition examines the growing clinical evidence for coverage of anti-obesity medications (AOMs) approved by the Food and Drug Administration in Medicare Part D. As the medical community’s understanding of disease states evolves, MAPRx…
